On this page ▾
The market expects Biocon to carry on much as it has.
At today’s share price, buyers are assuming Biocon grows about 16% a year, forever. Over the last ten years it actually grew about 19% a year. The two are close, so the share price does not need the business to improve or to stumble. It needs it to keep doing roughly what it already does.
- How it is valued: Discounted cash flow.
- What the price assumes: 16% growth, against 19% the model takes from its own record.
- Ten-year record: Between FY2019 and FY2026, Biocon's revenue went from ₹5,514 crore to ₹16,927 crore — it compounded at about 17% a year over 7 years.
- Biggest swing factor: Biosimilar launches. Main risk: Price competition.
01India's biotech pioneer
Biocon was founded in Bengaluru in 1978 by Kiran Mazumdar-Shaw. Its main business is Biocon Biologics, which makes biosimilars of insulin, cancer and immunology drugs and bought Viatris' biosimilars business in 2022.
It also makes generic APIs and formulations and owns a majority of Syngene International, a listed research and manufacturing services company.
02What the market is assuming
Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Biocon, next to what the model assumes from the company's own record.
The further apart these two numbers are, the bigger the bet a buyer at today's price is making.
03Biocon's record, in plain numbers
Between FY2019 and FY2026, Biocon's revenue went from ₹5,514 crore to ₹16,927 crore — it compounded at about 17% a year over 7 years. Net profit fell from ₹1,003 crore to ₹369 crore, about 13% a year — slower than revenue, so margins narrowed. In FY2026 it kept 2.2% of revenue as net profit — its weakest year in the period. The latest year added 10.9% to revenue, well behind its own long-run pace.
Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.
Revenue and net profit by year (₹ crore)
| Year | Revenue | Net profit | Margin |
|---|---|---|---|
| FY2019 | 5,514 | 1,003 | 18.2% |
| FY2020 | 6,367 | 871 | 13.7% |
| FY2021 | 7,106 | 846 | 11.9% |
| FY2022 | 8,184 | 772 | 9.4% |
| FY2023 | 11,174 | 643 | 5.8% |
| FY2024 | 14,756 | 1,298 | 8.8% |
| FY2025 | 15,262 | 1,429 | 9.4% |
| FY2026 | 16,927 | 369 | 2.2% |
04How Biocon gets valued — and why
Discounted cash flowThis business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.
05What decides Biocon's value
Biosimilar launches
New products in the US and Europe drive growth.
Debt reduction
Acquisition debt weighs on profit.
Syngene
Its listed stake adds value.
Generics
A steadier, smaller business.
06What could go wrong
- Price competition. Biosimilar prices fall as rivals enter.
- Regulatory delays. Approvals and inspections can slip.
- Leverage. Heavy debt magnifies setbacks.
07What the full Biocon valuation shows
Sign in free to see the complete Biocon valuation
- ✓Fair value per share — from a ten-year discounted cash flow, every step shown
- ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Biocon's value move
- ✓Bull, base and bear cases — and exactly which assumptions move between them
- ✓Peer comparison — against Sun Pharma, Dr Reddy's and other drugmakers
- ✓Downloadable report — the full write-up, yours to keep
08Questions people ask about Biocon
What are biosimilars?
Near-copies of biological medicines whose patents have expired.
Who founded Biocon?
Kiran Mazumdar-Shaw, in 1978.
What is Syngene?
A listed research and manufacturing services company majority-owned by Biocon.
Is Biocon overvalued?
At ₹364 the market is pricing in roughly 16% sustained growth, against the ~19% its own record supports. That is less than it has delivered — on these numbers the market is asking the business for less than its own record, which usually means it doubts the record repeats.
What is the intrinsic value of Biocon?
It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.
How much debt does Biocon carry?
Debt to equity stands at 0.32, down from 0.89 at the start of the period — the balance sheet is a core input to the cost of capital used here.